Video Explainer ReleasedDate: 2022-01-12
Like us, you probably know someone who has, or has had, Alzheimer’s disease. It is a progressively debilitating disease that destroys memory and other important mental functions. More than 30 million people worldwide have Alzheimer’s disease.
Alzinova AB is developing disease-modifying therapies against Alzheimer’s disease that specifically target the neurotoxic oligomers.
Learn more about the mechanism of action of the oligomer-specific vaccine ALZ-101, which is currently being evaluated in clinical trials and the monoclonal antibody ALZ-201. Watch the video below.